A Cambridge healthcare technology business has won UK government funding to determine whether its online psychology solutions can help fight diabetes distress.
Cambridge Consultants has accelerated growth plans for its drug delivery device development business in India following major expansion in the UK and United States.
PolyTherics, which owns Antitope Ltd at Babraham Research Park, Cambridge UK has extended a collaboration with US biotech MacroGenics Inc designed to produce novel antibody drug conjugates.
Napp Pharmaceuticals in Cambridge makes its debut this weekend in The Sunday Times BDO Profit Track 100 league table.
Seven companies from the Cambridge medical technology cluster have won a share of £12.7 million funding from SBRI healthcare in a UK government backed programme.
Horizon Discovery has broadened its technology range to give life scientists a broader base of research tools.
Domainex, a medical technology business anchored in Cambridge UK, reports a breakthrough in a salvo of studies seeking new treatments in life-limiting diseases.
Cambridge UK medical technology business Crescendo Biologics has hoisted its Series A financing to a new high of $32.5 million after EMBL Ventures invested $3.3M in a final close.
The Cambridge medical technology cluster and Norwich’s growing science segment are at the heart of a £12 million government initiative to give the genomics revolution a boost with the creation of new, dedicated DNA research hothouses.
Big Pharma giant Novartis is using medical technology expertise from Cambridge UK for a new auto-injector for sufferers of multiple sclerosis.
Cambridge UK medical technology business Vernalis has posted annual results ahead of market expectations and further progressed its portfolio of cough cold drugs.
A new generation of self-monitoring healthcare devices is being showcased in a Cambridge technology cluster company’s debut at the Gadget Show Live in the UK from April 9-13.
A globally gamechanging disease research hothouse is being opened in the Cambridge UK technology cluster by AstraZeneca and the Medical Research Council.
Regenerative medicines technology business Regenerys Ltd, which recently opened offices in Cambridge UK, has appointed a big-hitting CEO to drive a fresh phase of growth.
A Cambridge organisation, which supports procurement for NHS Trusts in the eastern region, has won a national award for a project which helped provide potentially life-saving nutrition for vulnerable premature babies.
The appetite of investors for a slice of Horizon Discovery shares sent the stock of the Cambridge UK personalised medicines business shooting skywards on its AIM debut this morning.
- Vernalis earns milestone cash from Japanese pharma
- Pioneering Cambridge alliance leads drive for new medicines
- Vectura reveals $45m US milestone
- Horizon makes history with AIM record $113m IPO
- AstraZeneca steps up Cambridge recruitment drive
- DNAdigest bids for $25k on Indiegogo
- Wall Street giant swoops for biotech duo
- Cambridge Cognition shares fall on bigger loss
- Dementia detective wins The Brain Prize
- Revolutionary tissue scanner set for production
- Novel compounds breakthrough via new technology
- Online psychology venture celebrates fresh success
- Abcam invests millions in brave new world
- Bug-busting Tristel courts US FDA
- IXICO grabs global glory after Phytopharm rescue
- Discuva wins Roche millions for superdrug to fight superbugs
Page 1 of 56